Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients

Journal of Gastroenterology

Volumn 46, Issue 7, 2011, Pages 929-937

  Ozeki, Itaru ^a   Akaike, Jun ^a   Karino, Yoshiyasu ^a   Arakawa, Tomohiro ^a   Kuwata, Yasuaki ^a   Ohmura, Takumi ^a   Sato, Takahiro ^a   Kamiya, Naohiro ^b   Yamada, Ichimaro ^b   Chayama, Kazuaki ^c   Kumada, Hiromitsu ^d   Toyota, Joji ^a  

^a Sapporo Kosei General Hospital   (Japan)

^b MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

^d TORANOMON HOSPITAL   (Japan)

Author keywords

Anemia; Hepatitis C therapy; Ribavirin; Telaprevir

Indexed keywords

HEMOGLOBIN; NONSTRUCTURAL PROTEIN 3; PEGINTERFERON ALPHA2B; RIBAVIRIN; TELAPREVIR; VIRUS RNA;

ADULT; AGED; ANEMIA; ANTIVIRAL SUSCEPTIBILITY; ANTIVIRAL THERAPY; ARTICLE; CASE REPORT; CLINICAL EFFECTIVENESS; CONCENTRATION LOSS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DECREASED APPETITE; DOSE RESPONSE; DRUG DOSE SEQUENCE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; FEVER; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; GENETIC VARIABILITY; GENOTYPE; HEADACHE; HEART PALPITATION; HEPATITIS C; HUMAN; INSOMNIA; JAPANESE; LEUKOCYTE COUNT; MONOTHERAPY; MUSCULOSKELETAL STIFFNESS; NAUSEA; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PRIORITY JOURNAL; PRURITUS; RASH; SIDE EFFECT; STOMACH DISCOMFORT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; URIC ACID BLOOD LEVEL; VIRUS GENE;

ANEMIA; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOMIC STRUCTURAL VARIATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; JAPAN; MIDDLE AGED; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 79960328806     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-011-0411-0     Document Type: Article

References (33)

1. A Wasley MJ Alter 2000 Epidemiology of hepatitis C: geographic differences and temporal trends Semin Liver Dis 20 1 16 10895428 10.1055/s-2000-9506 1:STN:280:DC%2BD3M%2Fit12ltg%3D%3D (Pubitemid 30421405)
2. GM Lauer BD Walker 2001 Hepatitis C virus infection N Engl J Med 345 41 52 11439948 10.1056/NEJM200107053450107 1:STN:280:DC%2BD3MzosFGrug%3D%3D (Pubitemid 32634271)
3. TJ Liang B Rehermann LB Seeff JH Hoofnagle 2000 Pathogenesis, natural history, treatment and prevention of hepatitis C Ann Intern Med 132 296 305 10681285 1:CAS:528:DC%2BD3cXhtlyku7g%3D (Pubitemid 30106261)
4. T Poynard MF Yuen V Ratziu CL Lai 2003 Viral hepatitis C Lancet 362 2095 2100 14697814 10.1016/S0140-6736(03)15109-4 1:CAS:528:DC%2BD3sXpvFylsb0%3D (Pubitemid 38035201)
5. MW Fried M Shiffman KR Reddy C Smith G Marinos FL Goncales Jr, et al. 2002 Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 975 982 12324553 10.1056/NEJMoa020047 1:CAS:528:DC%2BD38Xnt12rtb0%3D
6. MP Manns JG McHutchison SC Gordon VK Rustgi M Shiffman R Reindollar, et al. 2001 Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 958 965 11583749 10.1016/S0140-6736(01)06102-5 1:CAS:528: DC%2BD3MXntF2qtb8%3D (Pubitemid 32913521)
7. C Sarrazin S Zeuzem 2010 Resistance to direct antiviral agents in patients with hepatitis C virus infection Gastroenterology 138 447 462 20006612 10.1053/j.gastro.2009.11.055 1:CAS:528:DC%2BC3cXivVCgu7c%3D
8. RB Perni SJ Almquist RA Byrn G Chandorkar PR Chaturvedi LF Courtney, et al. 2006 Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease Antimicrob Agents Chemother 50 899 909 16495249 10.1128/AAC.50.3.899-909.2006 1:CAS:528:DC%2BD28XisFamt70%3D (Pubitemid 43327793)
9. C Hézode N Forestier G Dusheiko P Ferenci S Pol T Goeser, et al. 2009 Telaprevir and peginterferon with or without ribavirin for chronic HCV infection N Engl J Med 360 1839 1850 19403903 10.1056/NEJMoa0807650
10. JG McHutchison GT Everson SC Gordon IM Jacobson M Sulkowski R Kauffman, et al. 2009 Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection N Engl J Med 360 1827 1838 19403902 10.1056/NEJMoa0806104 1:CAS:528:DC%2BD1MXlsVGmtrc%3D
11. JG McHutchison MP Manns AJ Muir NA Terrault IM Jacobson NH Afdhal, et al. 2010 Telaprevir for previously treated chronic HCV infection N Engl J Med 362 1292 1303 20375406 10.1056/NEJMoa0908014 1:CAS:528:DC%2BC3cXksVyntrg%3D
12. H Okamoto S Mishiro 1994 Genetic heterogeneity of hepatitis C virus Intervirology 37 68 76 7814244 1:STN:280:DyaK2M7htlKktg%3D%3D (Pubitemid 24289503)
13. H Yoshizawa J Tanaka Y Miyakawa 2006 National prevention of hepatocellular carcinoma in Japan based on epidemiology of hepatitis C virus infection in the general population Intervirology 49 7 17 16166783 10.1159/000087257 (Pubitemid 41318170)
14. H Chung T Ueda M Kudo 2010 Changing trends in hepatitis C infection over the past 50 years in Japan Intervirology 53 39 43 20068339 10.1159/000252782
15. T Honda Y Katano F Urano M Murayama K Hayashi M Ishigami, et al. 2007 Efficacy of ribavirin plus interferon-α in patients aged 60 years with chronic hepatitis C J Gastroenterol Hepatol 22 989 995 17608843 10.1111/j.1440-1746.2006.04773.x 1:CAS:528:DC%2BD2sXpsFars78%3D (Pubitemid 47019853)
16. H Sezaki F Suzuki Y Kawamura H Yatsuji T Hosaka N Akuta, et al. 2009 Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral load Dig Dis Sci 54 1317 1324 18958621 10.1007/s10620-008-0500-y 1:CAS:528:DC%2BD1MXlsFKrtLY%3D
17. S Laperche F Lunel J Izopet S Alain P Dény G Duverlie, et al. 2005 Comparison of hepatitis C virus NS5b and 5' noncoding gene sequencing methods in a multicenter study J Clin Microbiol 43 733 739 15695672 10.1128/JCM.43.2. 733-739.2005 1:CAS:528:DC%2BD2MXit1aqs7Y%3D (Pubitemid 40256027)
18. K Chayama A Tsubota M Kobayashi K Okamoto M Hashimoto Y Miyano, et al. 1997 Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection Hepatology 25 745 749 9049229 10.1002/hep.510250342 1:CAS:528:DyaK2sXisVansbc%3D (Pubitemid 27106464)
19. N Akuta F Suzuki Y Kawamura H Yatsuji H Sezaki Y Suzuki, et al. 2007 Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels J Hepatol 46 403 410 17126448 10.1016/j.jhep.2006.09.019 1:CAS:528:DC%2BD2sXhtlCmtLs%3D (Pubitemid 46185701)
20. C Sarrazin TL Kieffer D Bartels B Hanzelka U Müh M Welker, et al. 2007 Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir Gastroenterology 132 1767 1777 17484874 10.1053/j.gastro.2007.02.037 1:CAS:528:DC%2BD2sXmsVyms7s%3D (Pubitemid 46677938)
21. TL Kieffer C Sarrazin JS Miller MW Welker N Forestier HW Reesink, et al. 2007 Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients Hepatology 46 631 639 17680654 10.1002/hep.21781 1:CAS:528:DC%2BD2sXhtFWhsr%2FL (Pubitemid 47436107)
22. S Susser C Welsch Y Wang M Zettler FS Domingues U Karey, et al. 2009 Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients Hepatology 50 1709 1718 19787809 10.1002/hep.23192 1:CAS:528:DC%2BD1MXhs1SjurrJ
23. P Qiu V Sanfiorenzo S Curry Z Guo S Liu A Skelton, et al. 2009 Identification of HCV protease inhibitor resistance mutations by selection pressure-based method Nucleic Acids Res 37 e74 19395595 10.1093/nar/gkp251
24. AS Perelson RM Ribeiro 2008 Estimating drug efficacy and viral dynamic parameters: HIV and HCV Stat Med 27 4647 4657 17960579 10.1002/sim.3116
25. Y Ohnishi T Tanaka K Ozaki R Yamada H Suzuki Y Nakamura 2001 A high-throughput SNP typing system for genome-wide association studies J Hum Genet 46 471 477 11501945 10.1007/s100380170047 1:CAS:528:DC%2BD3MXmtVynt74%3D (Pubitemid 32744120)
26. A Suzuki R Yamada X Chang S Tokuhiro T Sawada M Suzuki, et al. 2003 Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis Nat Genet 34 395 402 12833157 10.1038/ng1206 1:CAS:528:DC%2BD3sXmt1SkurY%3D (Pubitemid 36935332)
27. Y Tanaka N Nishida M Sugiyama M Kurosaki K Matsuura N Sakamoto, et al. 2009 Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C Nat Genet 41 1105 1109 19749757 10.1038/ng.449 1:CAS:528:DC%2BD1MXhtFaju73K
28. T Okanoue Y Itoh H Hashimoto K Yasui M Minami T Takehara, et al. 2009 Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study J Gastroenterol 44 952 963 19517057 10.1007/s00535-009-0087-x 1:CAS:528:DC%2BD1MXhtFCntr%2FL
29. F Suzuki Y Suzuki N Akuta H Sezaki H Yatsuji Y Arase, et al. 2010 Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir J Clin Virol 47 76 78 19857995 10.1016/j.jcv.2009.09.029 1:CAS:528:DC%2BD1MXhsFyksLfO
30. F Suzuki N Akuta Y Suzuki H Sezaki H Yatsuji Y Kawamura, et al. 2009 Rapid loss of hepatitis C virus genotype 1b from serum in patients receiving a triple treatment with telaprevir (MP-424), pegylated interferon and ribavirin for 12 weeks Hepatol Res 39 1056 1063 19619256 10.1111/j.1872-034X.2009.00548.x 1:CAS:528:DC%2BC3cXkvFOmsL4%3D
31. N Hiramatsu T Oze T Yakushijin Y Inoue T Igura K Mochizuki, et al. 2009 Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin J Viral Hepat 16 586 594 19552664 10.1111/j.1365-2893.2009.01106.x 1:STN:280:DC%2BD1MrlsF2nsA%3D%3D
32. HS Conjeevaram MW Fried LJ Jeffers NA Terrault TE Wiley-Lucas N Afdhal, et al. 2006 Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1 Gastroenterology 131 470 477 16890601 10.1053/j.gastro.2006.06.008 1:CAS:528:DC%2BD28XpsFyksL4%3D (Pubitemid 44142464)
33. P Simmonds J Bukh C Combet G Deléage N Enomoto S Feinstone, et al. 2005 Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes Hepatology 42 962 973 16149085 10.1002/hep.20819 1:CAS:528:DC%2BD2MXhtFGlsbbI (Pubitemid 41401136)